ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2483

Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry

Agnes Szentpetery1, Muhammad Haroon2, Phil Gallagher3, Eric J. Heffernan4 and Oliver FitzGerald2, 1Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4Radiology, St. Vincent's University Hospital, Dublin, Ireland

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Digital X-ray Radiogrammetry (DXR), DMARDs, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular in PsA following treatment. Digital X-ray radiogrammetry (DXR) is a sensitive method for quantifying changes in periarticular bone mineral density (DXR-BMD) in the early phase of the disease.  

The aim of this study was (1) to investigate DXR-BMD changes in early PsA and RA prior to and 3, 12 months after introducing an anti-rheumatic drug; and (2) to explore associations between disease-related variables and DXR-BMD.

Methods:

Recent-onset (<12 months), active, treatment naïve PsA and RA patients were selected. Hand BMD was measured by DXR based on digitized hand radiographs (Sectra, Sweden) at baseline, 3 and 12 months. Mean DXR-BMD (mg/cm2) values of both hands and changes in DXR-BMD (mg/cm2/month) were calculated and compared between the two groups at all time points. Changes in hand BMD were further analysed by dividing PsA and RA into 3 subgroups based on cut-offs for the categories normal, elevated BMD loss (>-0.25 mg/cm2/month) and highly elevated BMD loss (>-2.5 mg/cm2/month). DXR-BMD was correlated with clinical parameters including ESR, CRP, DAS28-CRP4v and HAQ.

Results:

64 patients (32 PsA, 32 RA) were included with median age 43 years. 95% of the patients were commenced on a DMARD therapy at baseline and 11.7 % (12.5% RA; 10.7% PsA) were also started on a TNF inhibitor. There were no patients taking anti-resorptive medications, 17.2% were on oral glucocorticoids (15.6% RA; 18.7% PsA) less than 10 mg per day. At 12 months 94.8% of the patients were on a DMARD and 34.5% on a TNF inhibitor (33.3% RA; 35.7% PsA). 

Mean DXR-BMD decreased in both diseases at 3 months and was significantly lower in RA at 12 months (p=0.004) compared to baseline. In contrast mean DXR-BMD increased in PsA over 12 months (p=0.07) and was higher at both 3 and 12 months compared to RA.

DXR-BMD loss were significantly higher in RA compared to PsA from baseline to 12 months (p=0.0005) and also from 3 to 12 months (p=0.0006). There were no bone loss in 91.7% of patients with PsA, but only in 40.7% of patients with RA between baseline and 12 months. Among all patients with elevated BMD loss, change in DXR-BMD was less marked in the PsA group compared to RA from baseline to 3 (p=0.018) and from 3 to 12 months (p=0.014). Highly elevated bone loss was present only in the RA cohort (7.5%) at 12 months.

Disease activity scores were significantly lower in PsA than in RA at baseline and 3 months. ESR, CRP, DAS28-CRP4v improved significantly in both diseases during the study. Mean DXR-BMD correlated negatively with ESR at 12 months in RA (r = -0.39; p= 0.038), however no other significant correlations between other clinical parameters and DXR-BMD were found.

Conclusion:

To our knowledge this is the first prospective study showing hand bone loss as early as 3 months as measured by DXR in both PsA and RA despite intervention of appropriate anti-rheumatic drug. After 1 year of treatment we observed cortical bone gain in PsA but further bone loss in RA supporting the hypothesis of different pathomechanisms being involved in hand bone remodelling in PsA.


Disclosure:

A. Szentpetery,
None;

M. Haroon,
None;

P. Gallagher,
None;

E. J. Heffernan,
None;

O. FitzGerald,

Pfizer, Abbott, BMS, MSD, Roche, UCB,

2,

Pfizer, Abbott, BMS, MSD, Janssen, Roche ,

5,

Pfizer, Abbott, Janssen, Roche, UCB ,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/periarticular-bone-gain-in-early-psoriatic-arthritis-but-not-in-rheumatoid-arthritis-following-anti-rheumatic-treatment-as-measured-by-digital-x-ray-radiogrammetry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology